Carbamazepine Extended-Release Capsules (Carbatrol) and Zelboraf

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

CarBAMazepine may significantly reduce the blood levels of vemurafenib, which may make the medication less effective in treating your condition. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of vemurafenib, which has been shown in vitro to be a substrate of the isoenzyme. According to the product labeling, administration of a single 960 mg dose of vemurafenib with the potent CYP450 3A4 inducer rifampin at a dosage of 600 mg once daily resulted in a 40% decrease in vemurafenib systemic exposure (AUC) relative to vemurafenib administered alone, with no effect on peak plasma concentration (Cmax). Reduced therapeutic efficacy of vemurafenib may occur.

MANAGEMENT: Concomitant use of vemurafenib with potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible during treatment with vemurafenib. If coadministration is required, the manufacturer recommends increasing the dose of vemurafenib by 240 mg (one tablet) as tolerated. Close monitoring for toxicities (e.g., QT prolongation, hepatotoxicity, nephrotoxicity, photosensitivity, dermatologic reactions, uveitis) is advised following dose increase. Two weeks after discontinuation of the strong CYP450 3A4 inducer, the vemurafenib dose that was taken prior to initiating the inducer may be resumed.

Carbamazepine Extended-Release Capsules (Carbatrol)

Generic Name: carbamazepine

Brand name: Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR, Tegretol, Tegretol XR

Synonyms: Carbamazepine, CarBAMazepine

What is Carbamazepine Extended-Release Capsules (Carbatrol)?

Zelboraf

Generic Name: vemurafenib

Brand name: Zelboraf

Synonyms: n.a.

What is Zelboraf?